Dementia with Lewy bodies (DLB) is a progressive neurological disorder characterized by cognitive impairment, behavioral changes, and fluctuations in alertness, as well as motor impairment. This form of dementia is named after Ernest Lewy, who first described Lewy bodies, specific protein inclusions found in the neurons of patients with the disease. Patients with LBD often have visual hallucinations, which can occur in the early stages, and the syndrome can be combined with features of Parkinsonism, making diagnosis difficult. One of the hallmarks of LBD is the presence of abnormal proteins, such as alpha-synuclein, which play a key role in the pathogenesis of the disease, causing degeneration of nerve cells.
History of the disease and interesting historical facts
Dementia with Lewy bodies was first described in 1912, when physician Ernest Lewy identified specific inclusions in neurons that were later named after him. However, the nature of the disease remained unclear for a long time, and it was not often mentioned in medical literature, as the attention of researchers was focused on Alzheimer's and Parkinson's disease for most of the 20th century. Since the beginning of the 21st century, LBD has received increasing attention due to new scientific data on pathogenesis, which allows us to better understand the mechanism of the disease and methods of its diagnosis. Interestingly, the analogies between familiar neurodegenerative processes and LBD are becoming increasingly noticeable, which opens up new horizons for research and potential therapies.
Epidemiology
Dementia with Lewy bodies is estimated to be one of the most common forms of dementia, along with Alzheimer's disease and Parkinson's disease. Approximately 10–15% of all cases of dementia in the elderly can be attributed to LBD. According to studies, the incidence of this condition increases with age, reaching 1-2% among people over 65 years old and 3-8% among people over 85 years old. Meta-analyses show that the prevalence of LBD in the population can vary from 0.37 to 4.8%. It is important to note that the disease can vary in clinical manifestations, which is also associated with individual characteristics of the work of neurotransmitters, such as dopamine and acetylcholine.
Genetic predisposition to this disease
To date, a number of studies have identified a number of genes associated with an increased risk of developing dementia with Lewy bodies. In particular, changes in the SNCA gene (encoding alpha-synuclein), as well as mutations in the PSEN1 and PSEN2 genes, which are responsible for familial forms of Alzheimer's, may also increase the risk of developing LBD. Although genetic predisposition plays a role, in most cases the disease manifests itself as a multifactorial disorder, where genetic factors interact with the environment. At the same time, having a family history of diseases such as Parkinson's disease may indicate an increased risk of developing LBD.
Risk factors for the development of this disease
Risk factors for developing Lewy body dementia include:
- Age - The risk increases with age, especially after age 65.
- Gender - Men are at greater risk than women.
- Heredity - having close relatives with dementia or Parkinson's disease increases the likelihood of developing the disease.
- Physical factors - previous head injuries or neurodegenerative disorders.
- Chemical factors – exposure to certain toxins such as heavy metals and pesticides.
- Comorbidities such as hypertension and diabetes.
Diagnosis of this disease
The diagnosis of DLB is based on a combination of clinical manifestations, laboratory and imaging studies. The main symptoms include:
- Cognitive impairment - problems with memory, attention, perception and planning.
- Mental symptoms - hallucinations, mood swings, depression.
- Motor disorders - tremors, rigidity, slowness of movement, altered gait.
Laboratory tests may include:
- Blood tests - to exclude metabolic and infectious diseases.
- Neuropsychological testing - to assess cognitive functions.
Radiological examinations:
- Magnetic resonance imaging (MRI) allows visualization of the brain structure, revealing atrophic changes.
- Positron emission tomography (PET) - allows detection of abnormal protein accumulations.
Differential diagnosis must be made with Alzheimer's disease and Parkinson's disease, since many symptoms can explain the similarity of these diseases.
Treatment
Treatment of dementia with Lewy bodies can be complex and should be based on an individual approach. General treatment includes:
- Cognitive therapy - to improve cognitive functions and support psychosocial well-being.
- Psychosocial interventions – creating a safe environment and emotional support.
Pharmacological treatment may include:
- Acetylcholinesterase inhibitors (eg, rivastigmine) - to improve cognitive function.
- Antipsychotics - to control hallucinations and other psychopathological conditions.
Surgical treatment is not used in most cases, but in some cases it may be considered in the presence of concomitant pathologies.
Other treatment approaches include:
- Physiotherapy – to improve motor functions.
- Functional training - to maintain daily activity.
List of drugs used to treat this disease
Among the main medications used in the treatment of DLB, the following can be distinguished:
- Rivastigmine (Exelon)
- Donepezil (Aricept)
- Galantamine (Razadyne)
- Olanzapine (Zyprexa)
- Quetiapine (Seroquel)
Disease monitoring
Monitoring the condition of a patient with dementia with Lewy bodies includes regular assessments of cognitive functions and general condition. Control stages:
- Regular visits to a neurologist or psychiatrist.
- Psychometric testing to monitor dynamics.
- Screening for side effects from medications.
The prognosis for patients with LBD varies, but the average life expectancy is 5 to 10 years from diagnosis. Complications can include progressive memory problems, difficulty performing daily tasks, and risk of falls and injuries.
Age-related features of the disease
Dementia with Lewy bodies may manifest itself differently depending on the age group. In patients over 70 years of age, the signs of the disease may develop faster and be expressed more intensely, due to the presence of comorbidities. In younger patients (aged 50-60 years), the symptoms may be less pronounced, but also require a more careful approach due to the high influence of cognitive and emotional factors.
Questions and Answers
- What are the main symptoms of Lewy body dementia? The main symptoms include cognitive impairment, visual hallucinations and motor disturbances, including parkinsonism.
- How is Lewy body dementia diagnosed? The diagnosis is made on the basis of clinical symptoms, laboratory and radiological studies.
- What treatment is indicated for this dementia? Treatment includes both drug and non-drug therapy with an emphasis on maintaining the patient's quality of life.
- What is the life expectancy of patients with LBD? Life expectancy is typically 5 to 10 years from diagnosis, but may vary depending on individual characteristics.
- Is there a genetic predisposition to LBD? Yes, some genes, such as SNCA, may increase the risk of developing the disease, especially when combined with other factors.
Advice from Dr. Oleg Korzhikov
When consulting a doctor, it is important to gather all available information about the symptoms and progress of the disease. Any changes in behavior and mood should be noted. It is also recommended to discuss with relatives possible support strategies, such as changing the environment for the patient's comfort. In addition, it is always useful to maintain finger activity and cognitive functions through various games and exercises. Take care of your health and promptly contact a specialist if symptoms occur.
